The Micro Cap Opportunity
Proven Strategies for the Astute Micro Cap & Nano Cap Stock Speculator
05/29/2008
The MCO Daily - Before the Bell for Friday May 30th, 2008
The Micro Cap Opportunity 'Daily'
‘Before the Bell’ for Friday, May 30th, 2008
On the Radar: DPBE, PAVC, ARSC, GNTA, CHTR, DSCO
This morning's top Micro Cap trading ideas include, Deep Blue Marine, Inc. (OTCPK: DPBE), Paivis Corp. (OTCPK: PAVC), American Security Resources Corp. (OTCBB: ARSC), Genta, Inc. (OTCBB: GNTA), Charter Communications, Inc. (NASD: CHTR), Discovery Laboratories, Inc. (NASD: DSCO).
DEEP BLUE MARINE, INC. (OTCPK: DPBE)
Up 17.14% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=DPBE.PK
| Deep Blue Marine (DPBE) is a company that brings together rapidly developing technology and a wealth of experience in both recovery and business. DPBE works on only thoroughly researched and permitted (where applicable) shipwrecks in a responsible manner that addresses environmental concerns while preserving priceless marine antiquities. |
|
| The crews of DPBE are highly qualified and have extensive backgrounds. Their areas of experience and expertise include research, salvage operations, marine survey, production of documentaries, all phases of diving, management and marketing of artifacts, and liaison with collectors and auction houses. | |
Recent DPBE News:
May 29, 2008 - Deep Blue Marine Inc. Announces Dividend to Take Effect June 3, 2008
Deep Blue Marine Inc. (Pink Sheets: DPBE) today announced completion of an asset sale agreement with Oceanic Research & Recovery, Inc. (Pink Sheets: ORRV), for the purchase of its equipment located in Key West, Florida, and the assumption of 100% of Deep Blue Marine's Florida operations.
As consideration, Deep Blue Marine received 100,000,000 shares of ORRV's restricted stock. This stock in turn will be distributed among the Deep Blue shareholders on a 1:1 exchange basis. These shares will be sent to the Deep Blue shareholders of record June 3, 2008, and will include Deep Blue's shareholders who have purchased stock in the open market up until the close of business June 3, 2008. These shares will be directly deposited through the DTC on these shareholders' behalf and credited to their accounts as of the record date.
Wilf Blum, President of DPBE, said, "We have sold no shares of the company from treasury since the 5 to 1 reverse split that took effect in March 2008. Therefore, if shareholders have not sold their shares they will get this dividend, if they do sell shares prior to June 3, 2008, they will not get the dividend for the shares they sold. So if you have 50,000 shares by June 3 you will get 50,000 shares of ORRV. This has given us a way to reward our faithful shareholders. As in all ventures of this nature investors should not invest money they cannot afford to risk."
PAIVIS CORP. (OTCPK: PAVC)
Up 15.00% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=PAVC.PK
Paivis, Corp. is a wholesale telecommunications carrier that sells prepaid "point-of-sale activated" and live cards. Paivis generates its revenues through the sale of prepaid calling cards and wireless services, and international wholesale termination. Products are sold throughout many of the country's major retail outlets, including Duane Reade, 7-Eleven, and Chevron.
Recent PAVC News:
May 29, 2008 - Trustcash Holdings, Inc. and Paivis, Corp. Provide Update on Merger Financing
TRUSTCASH HOLDINGS, INC. ("TRUSTCASH") (OTCBB: TCHH) and PAIVIS, CORP. ("PAIVIS") (PINKSHEETS: PAVC) today jointly provide an update of the merger financing required under the Merger Agreement between Trustcash and Paivis.
The requirements of financing under the Merger Agreement are progressing through the recently formed Trustcash subsidiary, TCHH Acquisition Corp.
It is through this subsidiary that Trustcash management has been planning the structure and execution of the financing plan for the merger.
Specifics will be provided as the details of the financing are completed.
Edwin Kwong, the Interim Executive Officer of PAIVIS, commented: "We are pleased by the developments from Trustcash regarding their efforts in raising the capital required under the Merger Agreement. We look forward to approving and subsequently completing these funding items with them as they occur."
About Trustcash
Through its Trustcash brand and website www.trustcash.com, the Company is a pioneer of anonymous payment systems for the internet. It developed a business based on the sale of a stored value card that can be used by consumers to make secure and anonymous purchases on the internet without disclosing their credit card or personal information. Trustcash provides to its customers the "Trustcash(TM)" payment card, which is sold in denominations ranging from $10 to $200 online through any of over 500 websites. Trustcash's non-reloadable, virtual Trustcash card is the only "stored value card" that can be purchased where no personal data is stored or available, providing a unique level of both security and privacy to the purchaser.
AMERICAN SECURITY RESOURCES CORP. (OTCBB: ARSC)
Up 24.14% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=ARSC.OB
ARSC is a holding company actively seeking to acquire companies and technologies that will advance the development of clean energy. ARSC, through its Hydra subsidiary, is developing high volume, mass producible hydrogen fuel cells. Its American Hydrogen subsidiary holds an exclusive worldwide license granted by Ohio University (www.ohio.edu) to commercialize an ammonia-to-hydrogen technology developed by Dr. Gerardine Botte of the Russ College of Engineering at Ohio University. For more information, please see: www.americansecurityresources.com
Recent ARSC News:
May 29, 2008 - American Hydrogen Corp. Not In Default; Working on Joint Ventures for Major Developments
Ben Schafer, President of American Hydrogen Corporation, a subsidiary of American Security Resources Corporation (OTCBB: ARSC), stated today, "Contrary to a statement in ARSC's most recent 10-Q, we are NOT in default on our license agreement with Ohio University. While our sister company Hydra Fuel Cell Corp. was fighting its patent lawsuit we fell behind in our obligations here, but we are working with Ohio to bring them current by the middle of the summer." Schafer further stated, "We are negotiating several JV projects to commercialize the ACE technology, including the development of a 250 kilowatt ACE unit and several waste to energy projects."
GENTA, INC. (OTCBB: GNTA)
Up 63.16% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=GNTA.OB
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com .
Recent GNTA News:
May 29, 2008 - Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Genta Incorporated (OTC Bulletin Board: GNTA) announced the results of long-term followup from a Phase 3 trial of the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, in patients with chronic lymphocytic leukemia (CLL). With 5 years of followup, new data show that patients who achieved either a complete response (CR -- the trial's primary endpoint) or a partial response (PR) have also achieved a statistically significant increase in overall survival. The data will be featured in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 2, 2008.
In the Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) with the addition of Genasense to the Flu/Cy regimen. (17% vs. 7%; P=0.025). In addition, the median duration of CR was also significantly longer for patients treated with Genasense (median not reached but estimated to exceed 36 months vs. 22 months).
Previous analyses showed a significant benefit in overall survival accrued to patients who attained CR. Extended followup has shown that all major responses (CR+PR) achieved with Genasense have now been associated with significantly increased overall survival compared with all major responses achieved with chemotherapy alone (median = 56 months vs. 38 months, respectively). At 5 years, 22 of 49 (45%) responders in the Genasense group remain alive compared with 13 of 54 (24%) responders in the chemotherapy-only group (HR = 0.6; P = 0.038).
Moreover, with 5 years of follow-up, 12 of 20 patients (60%) in the Genasense group who achieved CR are alive, 5 of these patients remain in continuous CR without relapse, and 2 additional patients have relapsed but have not required additional therapy. By contrast, only 3 of 8 CR patients in the chemotherapy-only group are alive, all 3 have relapsed, and all 3 have required additional anti-leukemic treatment.
The Company has requested a meeting with the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) to review this new information.
A scientific report of the initial safety and efficacy findings from this study was recently published (Journal of Clinical Oncology 25:1114, 2007).
About Chronic Lymphocytic Leukemia
CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at: http://www.lymphoma.org .
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
CHARTER COMMUNICATIONS, INC. (NASD: CHTR) Up 6.47% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=CHTR
Charter Communications, Inc. is a leading broadband communications company and the third-largest publicly traded cable operator in the United States. Charter provides a full range of advanced broadband services, including advanced Charter Digital(R) video entertainment programming, Charter High-Speed(TM) Internet access service, and Charter Telephone(TM) services. Charter Business(TM) similarly provides scalable, tailored and cost-effective broadband communications solutions to business organizations, such as business-to-business Internet access, data networking, video and music entertainment services and business telephone. Charter's advertising sales and production services are sold under the Charter Media(R) brand. More information about Charter can be found at www.charter.com.
Recent CHTR News:
May 29, 2008 - Charter Communications Announces Private Debt Exchange Offer for up to $500 Million of CCH II 10.25% Senior Notes Due 2010
Charter Communications, Inc. (NASDAQ: CHTR) ("Charter") announced today that its indirect subsidiaries, CCH II, LLC and CCH II Capital Corp. (collectively "CCH II") are commencing a private exchange offer (the "Offer") to exchange up to $500 million principal amount (subject to increase, the "Maximum Amount") of CCH II's existing 10.25% Senior Notes due 2010 (CUSIP Nos. 12502CAD3, 12502CAE1 and 12502CAM3) (the "Old Notes") for additional 10.25% Senior Notes due 2013 of CCH II (the "New Notes").
The purpose of the Offer is to improve Charter's financial flexibility by extending debt maturities.
The Offer is being conducted as a modified "dutch auction," pursuant to which holders of the Old Notes will have the opportunity to specify an exchange ratio at which they would be willing to exchange Old Notes for New Notes. Holders must submit tenders in the range of $1,047.50 to $1,077.50 principal amount of New Notes per $1,000 principal amount of Old Notes with amounts in the range specified in increments of $2.50 principal amount of New Notes per $1,000 principal amount of Old Notes.
Charter will accept Old Notes tendered beginning with the minimum exchange ratio and continuing in order of increasing increments of $2.50 in New Notes per $1,000 principal amount of Old Notes, until the aggregate principal amount of accepted Old Notes tendered equals the Maximum Amount (including an increase in such amount, if any). The highest exchange ratio specified with respect to Old Notes accepted for exchange in this process will be the "Clearing Exchange Ratio." If the aggregate principal amount of Old Notes tendered in the Offer exceeds the Maximum Amount, all Old Notes tendered at or below the Clearing Exchange Ratio will be accepted on a pro rata basis and Old Notes tendered above the Clearing Exchange Ratio will be rejected. All Old Notes tendered which are accepted will be paid in New Notes based on the same Clearing Exchange Ratio. Charter reserves the right, but is not obligated, to increase the Maximum Amount.
The Clearing Exchange Ratio will include an early participation payment of $30.00 in principal amount of New Notes per $1,000 principal amount of Old Notes (the "Early Participation Payment"). In order to receive the Early Participation Payment, investors must tender their Old Notes on or prior to 5:00 p.m. ET on June 11, 2008, unless extended. Eligible investors who validly tender their Old Notes after that time will receive, for their Old Notes tendered and accepted for exchange, a principal amount of New Notes equal to the Clearing Exchange Ratio for such Old Notes less the Early Participation Payment for such Old Notes.
Tendered notes may be validly withdrawn until 5:00 PM ET, on June 11, 2008, unless extended. The Offer will expire at 11:59 PM ET, on June 27, 2008, unless extended. The Offer is not subject to any minimum amount of Old Notes being tendered.
The New Notes will be unconditionally guaranteed by Charter Communications Holdings, LLC and will accrue interest from and including the settlement date. Holders who exchange Old Notes for New Notes will receive accrued and unpaid interest to, but not including, the settlement date.
The New Notes are being issued as part of the same series of notes as CCH II's $250 million aggregate principal amount of 10.25% Senior Notes due 2013 which were issued in September 2006 (the "Existing CCH II 2013 Notes") and will be treated as a single class under the governing indenture. The New Notes initially will be subject to certain restrictions on transfer, are expected to be issued with original issue discount and will have a separate CUSIP number from the Existing CCH II 2013 Notes.
The New Notes have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
The offer is being made only to qualified institutional buyers and to certain non-U.S. investors located outside the United States. The complete terms and conditions of the Offer are set forth in the informational documents relating to the Offer.
Documents relating to the Offer will only be distributed to noteholders who complete and return a letter of eligibility confirming that they are within the category of eligible investors for this private offer. Noteholders who desire a copy of the eligibility letter may contact Global Bondholder Service Corporation, the information agent for the Offer, at (866) 470-3700 (U.S. Toll-free) or (212) 430-3774.
DISCOVERY LABORATORIES, INC. (NASD: DSCO)
Up 4.49% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=DSCO
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' technology produces a peptide-containing synthetic surfactant that is structurally similar to pulmonary surfactant. Discovery Labs believes that, with its proprietary technology, SRT has the potential, for the first time, to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patients.
SURFAXIN(r), the Company's lead product from its SRT pipeline, is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. SURFAXIN is also being developed for other neonatal and pediatric indications. AEROSURF(tm), Discovery Labs' aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.
Recent DSCO News:
May 29, 2008 - Discovery Labs and FDA to Meet On June 18, 2008 to Clarify Limited Items in SURFAXIN Approvable Letter
Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that it has received written notification from the U.S. Food and Drug Administration (FDA) that a meeting has been scheduled for June 18, 2008 via teleconference. This meeting is intended to confirm with the FDA Discovery Labs' approach to address the limited key remaining items necessary to gain U.S. marketing approval of SURFAXIN(r) (lucinactant) for the prevention of RDS in premature infants. On May 1, 2008, Discovery Labs received an Approvable Letter from the FDA for SURFAXIN that reflected notable progress towards gaining FDA approval.
On May 14, Discovery Labs submitted a pre-meeting information package to the FDA which also served as a formal request to schedule the meeting. This information package discussed Discovery Labs' proposals for responding to select items identified in the Approvable Letter. The Company believes that the most important items involve justifying and finalizing one acceptance criterion for SURFAXIN's biological activity and limited acceptance criteria for lipid drug substance impurities. Discovery Labs believes it can satisfy these items with data that are already available and wants to confirm its approach with the FDA prior to filing a formal response to the Approvable Letter.
The recent Approvable Letter reflects key achievements towards gaining FDA approval for SURFAXIN including agreeing with the FDA on the SURFAXIN package insert and successfully concluding a pre-approval inspection of Discovery Labs' manufacturing operations. The Approvable Letter does not require any additional clinical trials to gain SURFAXIN approval. If the June 18 meeting with the FDA positively confirms Discovery Labs' approach to addressing the Approvable Letter items, Discovery Labs anticipates submitting a formal response to the Approvable Letter in June 2008. Discovery Labs continues to believe that this response may potentially be designated by the FDA as a Class 1 resubmission with a review target of 60 days. The overall timeline to gain SURFAXIN approval may be shortened or extended depending on the outcome of the meeting and other related factors.
